Monitor the next 10-Q filing for disclosure of the full separation agreement and any impact on compensation expenses. The departure of a financial officer warrants attention, but the orderly transition and lack of immediate replacement suggest a manageable transition.
Price Chart
Executive Summary
NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, will depart on August 31, 2026, with a separation agreement providing 12 months of base salary, a pro-rated bonus, and extended vesting of equity awards through January 2027. The departure appears planned and orderly.
Key Facts
- Chief Accounting Officer Louise Kooij is departing effective August 31, 2026
- Departure was mutually agreed upon and not unexpected
- Separation agreement includes 12 months of base salary, pro-rated 2026 bonus, and accrued vacation
- Equity vesting extended through January 10, 2027, with exercise period until February 10, 2027
- No replacement has been announced
Financial Impact
Approximately 12 months of base salary plus pro-rated bonus (exact dollar amounts undisclosed)
Risk Factors
- Potential disruption in financial reporting during transition
- Increased workload for remaining finance team
- Uncertainty around succession planning for key financial roles
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-177406 |
| Document: 0001193125-26-177406-index-headers.html | 0001193125-26-177406 |
| Document: 0001193125-26-177406-index.html | 0001193125-26-177406 |
| Document: 0001193125-26-177406.txt | 0001193125-26-177406 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 17w ago | 8-K | $24.90 $16.51 | ▼ −33.68% | ▼ −36.18% | $12.65 (−49.19%) |
May 7, 2026 21w ago | 8-K | $22.80 $15.00 | ▼ −34.21% | ▼ −38.04% | $12.65 (−44.52%) |
Apr 24, 2026 23w ago | 8-K | $19.10 $19.38 | ▲ +1.47% | ▼ −3.31% | $12.65 (−33.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access